Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (TSX: $WEED.TO) (NYSE: $CGC) (OTCQB: $SING) (OTC: $ORGH) (OTCQB: $AXIM) (TSXV: $AVCN.V) (TSXV: $PCLO.V) (OTC: $PHCEF)
Delta, Kelowna BC –August 8, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) announced that it has partnered with one of the largest global sellers of premium cannabis accessories, Greenlane Holdings, Inc, (NASDAQ: GNLN) that gives Greenlane exclusive distribution rights of Storz & Bickel vaporizers throughout the United States.
Storz & Bickel, a subsidiary of Canopy Growth based in Tuttlingen, Germany, has a 22-year history as the global leader in vaporizer design. The company has won accolades for developing an automated and internationally certified factory, achieving ISO 13845 certification in 2009 and exporting to over 50 markets around the world. Storz & Bickel first introduced the world-renowned Volcano® product line in 2000 and since then has worked tirelessly to continue innovating and perfecting the industry's leading tabletop vaporizer, in addition to their successful portable handhelds including the Crafty® and Mighty® devices.
Greenlane has been Storz & Bickel's exclusive U.S. distribution partner since January 2018 and the new agreement signed with Canopy Growth will allow for robust growth in the American market along with continued distribution to the Canadian market. Greenlane boasts an extensive distribution network within North America which includes over 11,000 retail locations spanning smoke and vape shops and licensed cannabis dispensaries. Through their distribution channels, Greenlane will bring Storz & Bickel's newest desktop vaporizer technology—the Volcano Hybrid—to market. The Hybrid model offers improved airflow management, faster heat-up times, easy to use touch display, a rotatable tube system for an alternate inhalation method and increased safety and functionality through Bluetooth app control.
"Establishing and extending this exclusive partnership with Greenlane has played an important role in cementing Storz & Bickel's brand reputation for quality, safety and performance in the United States." commented Peter Popplewell, PhD., Canopy Growth Chief Technology Officer. "We have seen tremendous success with their smaller handheld devices, including the Mighty, and we are excited to introduce Storz & Bickel's latest update on the Volcano as consumers continue to be drawn towards top-quality vaporizer technology."
SinglePoint (OTCQB: SING) announced today that it has signed a master distribution agreement with Pure Products LLC to become the primary sales and marketing solution for the company’s line of “Pure Hemp” cigarettes.
This distribution agreement is a natural fit for SinglePoint CEO Greg Lambrecht as previously he led Premium Cigars International to an IPO NASDAQ listing. The company distributed and serviced over 30,000 accounts throughout North America. “We are excited for this opportunity. I have many contacts still in the business from my prior distribution company and look forward to bringing Pures’ hemp cigarettes to market. There is a massive opportunity and we have been seeing retailers looking for this type of product during our due diligence into the space,” states Greg Lambrecht CEO SinglePoint.
According to Steve Ross, President of Pure Products LLC, "A phenomenon is occurring where people are substituting or modifying tobacco consumption with low THC cannabis/hemp cigarettes containing less than .3% THC. We believe we have the best all-natural hemp cigarette in the market and are tremendously excited to partner with Singlepoint to accelerate our product placement into retail outlets nationwide.”
Singlepoint President Wil Ralston stated, “Our team is excited to represent this outstanding product and we are confident that we can help establish “Pure” as a meaningful leader in the natural hemp cigarette category. We believe retail outlets and specialty shops across the country are anxious to dedicate shelf space to CBD, especially hemp cigarettes. The Pure brand brings an elevated standard of product to the market, enhancing the consumer’s experience while adding revenues and profits to these retailers.”
Ralston added, “Not long ago, SinglePoint made a significant commitment to be a major provider in the industrial hemp space and the agreement with Pure Products is another bold move for the company to solidify our place in the industry. Teaming with Steve Ross and the Pure Products team accelerates our plan to put finished goods into retail stores.”
OrgHarvest, Inc. (OTC: ORGH) announced a license agreement has been entered into by and between OrgHarvest Inc. and Keith DeSanto of Rhamnolipid, Inc. in which Rhamnolipid has invented and filed numerous pest and disease control agricultural application patents for rhamnolipid products in the cannabis and hemp industries. Hemp and cannabis rhamnolipid applications include specific blends, peptides, rhamnolipid liposomes, injection technology and pest repellants.
“The cannabis and hemp industries have been plagued by various diseases, pests and fungi in the cultivation process. We are excited to announce that Mr. DeSanto will be joining the OrgHarvest team as our vice president of technology, bringing with him this game-changing rhamnolipid technology. This will mean fewer crop failures and preventable losses to our bottom line,” said Frank Celecia, CEO of OrgHarvest.
OrgHarvest seeks to launch cannabis cultivation and production operations in Las Vegas, Nevada, employing a high-tech, 100,000-square-foot glass greenhouse imported from the Netherlands that has the capacity to produce 450 pounds of cannabis flower per week, enabling the Company to potentially quadruple revenues after its second year of operation.
Carlos Calixto, COO of OrgHarvest, was very pleased to see the test results of these patent-pending rhamnolipid applications. The Company is focused on the acquisition of and/or joint venturing with cannabis dispensaries as well as the production and distribution of cannabis flower with high THC values and oils used in manufacturing edibles, beverages and pharmaceuticals. The Company expects to find a tremendous market in the sale of rhamnolipids to the hemp industry.
OrgHarvest’s competitive advantages include risk diversification through the approach of growing cannabis using a high-tech custom Dutch glasshouse manufactured in the Netherlands, which offers a unique combination of advantages unmatched by OrgHarvest’s competitors. Compared to other cannabis operations, the Company differentiates itself by offering a facility that can provide higher-quality and pest-free flowers and a stronger focus on developing strains and new products using exclusive patented technology.
AXIM® Biotechnologies, Inc. (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent (Application No. 16/293,136) on anti-microbial compositions comprising cannabinoids, specifically CBG. The USPTO granted this patent allowance from AXIM’s patent application filed on March 5, 2019.
All products that AXIM has the opportunity to produce under this patent will be made using CBG, a strong anti-microbial agent. AXIM aims to utilize this patent in the development of products for the treatment of symptoms associated with fungal-related diseases, including tinea pedis, commonly known as athlete’s foot. AXIM intends to develop future products under this patent in an aerosol form and foot powder for easy application. Other products with different anti-microbial applications are also considered for development under this patent.
According to Grand View Research, the global antifungal drugs market is expected to reach $12.7 billion by 2025, giving AXIM the opportunity to offer its unique products to a large market.
“We have recognized the importance of patents since our early days with our well-known patent on chewing gum as a delivery mechanism for all cannabinoids,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “We look forward to continuing to lead cannabis innovation with this patent and future patents as the industry advances in both market growth and legitimacy.”
Once granted this patent, AXIM will hold eight issued patents and 11 pending patent applications.
Avicanna Inc. (TSX: AVCN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that it has entered into an agreement with Sigma Analytical Services Inc. to establish a joint venture for the testing of cannabis and cannabis-based products in Colombia.
The joint venture will leverage Sigma Analytical's expertise, methodology, and intellectual property in cannabis and derived product testing to establish a laboratory to test cannabis genetics and products. Independent analytical services will be managed and operated by an operating company with complete adherence to techniques and procedures developed and implemented by Sigma Analytical. The laboratory is expected to be located within the SMGH facilities and testing services will be provided to Santa Marta Golden Hemp S.A.S. ("SMGH") and Sativa Nativa S.A.S. ("Sativa Nativa"), two subsidiaries of Avicanna, and are expected to also be offered to a variety of large licensed producers to small scale partner farmers. The parties anticipate that the laboratory will be the first cannabinoids-only, analytical laboratory and independent testing service in South America to meet Health Canada, European Pharmacopeia, US Pharmacopeia, and compliant to EU GMP standards. With technical transfer currently underway, the completion and launch of the laboratory services is expected to occur early in the fourth quarter of 2019.
The laboratory will provide a comprehensive suite of cannabis specific testing, which will include pesticides, heavy metals, residual solvents, aflatoxins, microbial, genotyping, and cannabinoid and terpene profiling.
Current and proposed legislation requires independent laboratory testing for cannabis extract for future medical sales and export. However, as full-suite testing in line with global standards is currently unavailable in Colombia, it requires many companies to go through the lengthy process to export samples for validated testing results.
PharmaCielo Ltd. (TSXV:PCLO) (OTC:PHCEF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., today announced it has joined the TruTrace Technologies, Inc. (CSE:TTT) (OTCQB:TTTSF) and Shoppers Drug Mart initiated medical cannabis pilot verification program. PharmaCielo is the first international medical cannabis producer to join this seed-to-sale tracking initiative.
"We are pleased to have a recognized international medical cannabis producer joining and supporting our technology and the Canadian Pilot Program. As a new and burgeoning industry that impacts people's health and wellbeing, it is imperative to build accountability into the supply chain and product offerings. I am thrilled to have partners like PharmaCielo joining the platform with Shoppers, sharing the same vision that we have and representing the global industry perspective to push it forward," said TruTrace Technologies CEO Robert Galarza.
"The product registration hub is the right type of initiative the industry needs to bring it on par with the pharmaceutical and food industries in terms of full transparency and traceability," said David Attard, CEO with PharmaCielo Ltd. "We see great value in this technology and its importance to the industry. PharmaCielo fully supports this initiative, as it aligns with our commitment to adhering to the highest operational and ethical standards in everything we do."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
